Stockscreener 앱 받기
16.30
5.73%
-0.99
시간 외 거래:
16.30
Novocure Ltd 주식(NVCR)의 최신 뉴스
Does NovoCure’s Shift Into Russell Value Indexes Recast NVCR’s Core Investment Narrative? - simplywall.st
Price to book forward of NovoCure Ltd. – FWB:038 - TradingView
Price to earnings forward of NovoCure Ltd. – FWB:038 - TradingView
NVCR stock. NovoCure’s business case stays in view. - ad-hoc-news.de
Is NovoCure (NVCR) Cheap As TRIDENT Fallout Clouds Its Valuation? - simplywall.st
NVCRNovoCure Ltd Volatility & Greeks - Finviz
NovoCure (NVCR) CHRO acquires 1,905 discounted shares in ESPP purchase - Stock Titan
NovoCure (NVCR) CEO adds 1,905 shares through 2025 employee share purchase plan - Stock Titan
NovoCure (NVCR) General Counsel adds 1,299 ESPP shares to holdings - Stock Titan
NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan - Stock Titan
NovoCure's Cancer Treatment Device Option Pax Gets European Approval - Yahoo Finance
Novocure sets July 23 call for Q2 2026 results before markets open - Stock Titan
Novocure's Optune Pax Receives EU CE Mark for Pancreatic Cancer Treatment - GuruFocus
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Novocure wins CE Mark for Optune Pax pancreatic cancer treatment - grafa.com
Novocure (NVCR) Gains CE Mark for New Pancreatic Cancer Treatmen - GuruFocus
Novocure receives CE Mark for pancreatic cancer device in Europe By Investing.com - Investing.com Nigeria
Novocure’s Optune Pax® Wins CE Mark for Pancreatic Cancer After Phase 3 Success in PANOVA-3 Trial - Minichart
Novocure receives CE Mark for pancreatic cancer device in Europe - Investing.com
Optune Pax CE Mark expands Novocure (NASDAQ: NVCR) pancreatic cancer reach - Stock Titan
Wearable pancreatic cancer device Optune Pax wins CE Mark in Europe - Stock Titan
NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start - Sahm
NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh - TradingView
NovoCure (NVCR) Could Be 42% Undervalued On Mixed TRIDENT Trial Results - simplywall.st
NovoCure Ltd. Actuals & Estimates (NASDAQ:NVCR) - TradingView
NovoCure Ltd. Actuals & Estimates (LSX:A140ML) - TradingView
NVCR Forecast — Price Target — Prediction for 2027 - TradingView
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages NovoCure Limited (NVCR) Investors to Inquire about Securities Investigation | NDAQ:NVCR | Press Release - Stockhouse
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $46 - Moomoo
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? - Yahoo Finance
NovoCure StockSunday background on TTFields cancer therapy specialist - AD HOC NEWS
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm - Business Wire
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - Sahm
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com Canada
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Financial Times
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $46 - Moomoo
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novocure stock tumbles after trial misses primary endpoint By Investing.com - Investing.com Australia
Why is Novocure stock plummeting today? By Investing.com - Investing.com Australia
2.36%
자본화:
|
볼륨(24시간):